Back to News
Market Impact: 0.2
Cerenome Expands CNSide Coverage Through Blue Cross Blue Shield Michigan Deal; Stock Up
Source: Nasdaq
Healthcare & BiotechCompany Fundamentals
CNSide Diagnostics, a wholly owned Cerenome subsidiary, signed an in-network provider agreement with Blue Cross Blue Shield of Michigan effective September 1, 2026. The agreement expands insurance-network access for the CNSide cerebrospinal-fluid diagnostic offering and could support patient adoption, though no financial terms or revenue impact were disclosed.
AllMind Terminal
AI-powered research, real-time alerts, and portfolio analytics for institutional investors.
Request TrialMarket Sentiment
Overall Sentiment
mildly positive
Sentiment Score
0.30
Ticker Sentiment
CNSY0.55
More News
- South Korean solar stocks jump as curbs on Chinese sector expected to remain in place
- Meta is breaking out after introducing Muse AI agent. Where the stock is going, according to the charts
- Heidi CEO on AI in Healthcare, $900M valuation
- Australia’s IDP shares drop after rejecting $494 mln Blackstone offer
- Lennar shares pop as Berkshire builds almost a 10% stake in beleaguered homebuilder
- S&P 500 Profits Are on Track for a Third Straight Quarter of 25%+ Growth. The Index Hasn't Kept Up.